Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

TARRYTOWN, N.Y., Oct. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2016 in a private placement.  The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.  The Company also intends to grant to the initial purchaser a 13-day option to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions.

The Company intends to use a portion of the proceeds of the offering, together with the proceeds from the warrant transactions, to fund the cost of the convertible note hedge transactions in connection with the offering, each as described below.  The Company intends to use the remaining net proceeds for general corporate purposes.

The notes will be general senior unsecured obligations of the Company.  The notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and stock, at the Company's option.  The notes will mature on October 1, 2016 unless previously repurchased or converted in accordance with their terms prior to such date.  The interest rate, conversion rate, conversion price and other terms of the notes will be determined at the time of the pricing of the offering.

In connection with the offering of the notes, the Company plans to enter into privately negotiated convertible note hedge and warrant transactions with counterparties that may include the initial purchaser and/or its affiliates.  The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, the number of shares of the Compa
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... 28, 2015 BioNorth Texas (BioNorthTX), ... representing the life sciences industry in northern region ... meeting at The Foundry in Dallas on April ... brought together a broad spectrum of biotech professionals ... organization's early successes in partnering with key life ...
(Date:5/28/2015)... , May 28, 2015 Biscayne ... anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology ... the 2015 ASCO Annual Meeting. The data show that ... Biscayne,s anti-cancer GHRH blockers, is present on many primary ... findings suggest that GHRH antagonists could have broad anti-cancer ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
... BEIJING, Oct. 24, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, ... of the leading plasma-based biopharmaceutical companies in the People,s ... included in Forbes Magazine,s annual list of Asia,s "200 ... Company was also named to the same list for ...
... LONDON, October 24, 2011 Silence ... interference (RNAi) therapeutics company, today announced that it ... Inc. ("Mirna"), a biopharmaceutical company pioneering microRNA-based therapeutics ... Silence,s proprietary AtuPLEX™ and DBTC delivery systems for ...
Cached Biology Technology:Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 2Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 3Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 4Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 5Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics 6
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... A University of Minnesota research team featuring researchers from the ... Drug Design has developed a new delivery system for a ... an effective treatment for the human immunodeficiency virus (HIV). ... decitabine and gemcitabine to be delivered in pill form, marks ...
... WASHINGTONA George Washington University researcher will receive $1.3 million ... of Diabetes and Digestive and Kidney Diseases (NIDDK) for ... diabetes develops, possibly informing the development of novel treatments ... important given 150 million people worldwide suffer from type ...
... regularly, but still aren,t seeing improvements in your health, there ... report published in the September issue of The ... may not be the problem, but what,s in what you ... evidences for rethinking the way of addressing risk assessment especially ...
Cached Biology News:Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs 2Type 2 diabetes study to examine role amylin plays in disease 2'Safe' levels of environmental pollution may have long-term health consequences 2
... a complete assay system for the measurement ... serum or plasma. The assay incorporates the ... IDS 1,25D RIA followed by quantitation by ... to use reagents, no organic or solvent ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
anti-achaete...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Biology Products: